Exchange: NASDAQ·Updated 07:59 PM EST

VIVS News

News
all
press releases
VivoSim Labs (VIVS) Stock Jumps 21% After Hours: What's Driving the Move
VivoSim Labs shares jumped 21.10% after hours following a seven-figure toxicology testing agreement with a global pharmaceutical company.read more...
Benzinga
VivoSim Labs (VIVS) Stock Jumps 21% After Hours: What's Driving the Move
VivoSim Labs shares jumped 21.10% after hours following a seven-figure toxicology testing agreement with a global pharmaceutical company.read more...
Benzinga
More News
Gainers VivoSim Labs (NASDAQ:VIVS) shares increased by 82.0% to $0.22 during Thursday's regular session. The market value of their outstanding shares is at $2.4 million. Marker Therapeutics (NASDAQ:MRKR) sharesread more...
Benzinga
The pharmaceutical industry loses billions each year on drug candidates that perform well in animal testing but ultimately fail in human trials, most often because of safety concerns. As regulators push for more predictive human-based testing models, companies developing next-generation preclinical technologies are beginning to attract growing attention from both pharmaceutical partners and investors.Shares of VivoSim Labs, Inc. (Nasdaq: VIVS) are climbing Wednesday after the company announced it received a $5 million milestone payment from Eli Lilly while also issuing fiscal 2027 guidance ...
AllPennyStocks.com
The pharmaceutical industry loses billions each year on drug candidates that perform well in animal testing but ultimately fail in human trials, most often because of safety concerns. As regulators push for more predictive human-based testing models, companies developing next-generation preclinical technologies are beginning to attract growing attention from both pharmaceutical partners and investors.Shares of VivoSim Labs, Inc. (Nasdaq: VIVS) are climbing Wednesday after the company announced it received a $5 million milestone payment from Eli Lilly while also issuing fiscal 2027 guidance ...
AllPennyStocks.com
VivoSim Labs shares climbed after receiving a $5 million Eli Lilly milestone payment and forecasting more than 500% revenue growth in FY2027.read more...
Benzinga
Small-cap healthcare and emerging growth stocks continue to generate investor interest as multiple companies announced significant regulatory, scientific, and strategic developments. $NTHI, $ERNA, $VIVS, $LLY, $VEEE, $SOBR
24-7 Market News
VivoSim Labs (NASDAQ:VIVS) delivered two developments that could significantly strengthen its investment narrative: a $5 million milestone payment from Eli Lilly tied to a previously divested inflammatory bowel disease drug program, and guidance calling for more than 500% revenue growth in fiscal 2027 as demand accelerates for its human-based preclinical testing platform.
24-7 Market News
Danaher, Vertex Pharmaceuticals, Moderna, Vaxcyte, argenex, VivoSim Labs, and ImmunityBio are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks...
MarketBeat
Danaher, Vertex Pharmaceuticals, Moderna, Vaxcyte, argenex, VivoSim Labs, and ImmunityBio are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks...
MarketBeat
Danaher, VivoSim Labs, Moderna, Vaxcyte, and Dianthus Therapeutics are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies...
MarketBeat

Advertisement|Remove ads.